GPN Vaccines Raises US$10M to Propel Gamma-PN Phase 2
Pneumonia Vaccines Take a Bold Step GPN Vaccines is steering its course with a US$10 million private placement, aiming to shake up a traditionally complex vaccine market. This clinical-stage biotech is throwing down the gauntlet with Gamma-PN™, its lead candidate that challenges existing serotype-specific pneumococcal vaccines. The big idea? Bypass the mess of adding...
Continue Reading